Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS)
Status:
Completed
Trial end date:
2009-09-04
Target enrollment:
Participant gender:
Summary
This was a 2-part study of dexpramipexole in patients with ALS.
Part 1 was a randomized, placebo-controlled, multi-center study to evaluate the safety,
tolerability, and clinical effects of oral administration of 3 dosage levels of
dexpramipexole vs. placebo for 12 weeks.
Part 2 was a randomized, double-blind, 2-arm, parallel group, extension study evaluating the
safety, tolerability, and clinical effects of oral administration of 2 dosage levels of
dexpramipexole for up to 72 weeks.